Pembrolizumab and Lenvatinib is named as an intervention in 2 current clinical trials in our China and Netherlands registers. 1 is recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Peking Union Medical College Hospital (1). The most-studied condition is Biliary Tract Neoplasms Immunotherapy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT06230471 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy
|
Phase 2 | Recruiting | Peking Union Medical College Hospital | China |
|
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
NCT07368985 · ClinicalTrials.gov ↗ · Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
|
Phase 2 | Not yet open | Prof. Dr. Remi A. Nout | Netherlands |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Peking Union Medical College Hospital | 1 |
| Prof. Dr. Remi A. Nout | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Netherlands | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Netherlands registers name Pembrolizumab and Lenvatinib as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Peking Union Medical College Hospital (1) and Prof. Dr. Remi A. Nout (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pembrolizumab and Lenvatinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pembrolizumab and Lenvatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pembrolizumab and Lenvatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.